Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
9,878 total articles
Simrat Randhawa, Executive Vice President and Head of Research & Development at Dianthus Therapeutics, Inc., executed a transaction involving the sale of approximately $2.4 million worth of company common stock on June 1, 2026. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan following the exercise of stock options. The arti…
Mark Coleman, a director at Axsome Therapeutics, Inc., recently executed multiple sales totaling 17,537 shares of common stock, valued at approximately $4.02 million. These sales, which occurred between May 29 and June 2, 2026, were conducted under an established trading plan. The activity takes place as AXSM stock trades near its historical highs,…
A director of Star Equity Holdings purchased additional shares of common stock in late May 2026. This transaction occurs against a backdrop of ongoing corporate activities, including an At Market Issuance Sales Agreement for preferred stock, updated executive compensation plans, and the completion of a significant sale-leaseback transaction involvi…
Alignment Healthcare, Inc. (NASDAQ:ALHC) saw its President - MSO, Mark D. Kent, acquire a significant block of common stock in early June 2026. This transaction occurred alongside the release of robust first-quarter 2026 financial results and several key leadership appointments at the company, suggesting internal confidence amid operational growth.
Phibro Animal Health Corp. director E. Thomas Corcoran recently acquired 10,000 shares of the company's Class A Common Stock on May 29, 2026, valued at $317,700. This transaction occurred while the stock was trading down significantly over the past week. The purchase comes against a backdrop where the firm reported strong financial results for the …
The recent activity of DuPont de Nemours, Inc. (NYSE:DD) CEO Lori Koch involving the sale of company common stock is occurring against a backdrop of significant corporate positive developments for DuPont. Ms. Koch executed two separate transactions in May and June 2026. Concurrently, the company reported strong first-quarter results that exceeded a…
Teresa Briggs, a director at DocuSign, Inc., executed multiple stock transactions in May and June 2026. She sold shares pursuant to a Rule 10b5-1 plan and simultaneously acquired shares resulting from the vesting of Restricted Stock Units (RSUs). Separately, she was granted additional RSUs. The company continues to announce significant technologica…
Docusign director James A. Beer executed a sale of common stock on June 2, 2026, through a pre-arranged trading plan. This transaction occurred as the company prepares for its earnings report. The article details Mr. Beer's recent vesting and granting of Restricted Stock Units (RSUs), alongside Docusign's major platform enhancements including new A…
Anna Marrs, a director at DocuSign, Inc., executed a sale of company common stock on June 2, 2026. This disposal was managed through a Rule 10b5-1 trading plan. The transaction occurred when the stock traded near $55.10, shortly before the release of earnings reports and following recent news regarding DocuSign's expansion into AI capabilities and …
Senior Vice President Claire Xu sold a portion of her NovaBridge Biosciences shares, while the company simultaneously reported encouraging data from its Phase 2a study for VIS-101 and received confirmation that its lead asset, givastomig, may qualify for accelerated FDA approval. Furthermore, NovaBridge appointed Mark Hagler as President and Chief …
Rambus director, Eric B. Stang, sold a significant block of company shares totaling $730,000 on June 1, 2026. This transaction occurred against a backdrop of positive corporate developments for Rambus Inc., including the introduction of new AI-enabled components and upgrades to its financial guidance from major investment banks.
Charles D. Boynton, Chief Financial Officer of Nextpower Inc., recently sold a substantial block of common shares. This sale occurred against a backdrop of positive analyst activity and major corporate news, specifically the planned acquisition of Prevalon Energy, which is expected to bolster Nextpower's position in solar power technology.
Robert Fauber, President and CEO of Moody's Corp, recently sold a substantial amount of company stock. This activity occurred against a backdrop of varied analyst sentiment and positive operational news for the firm.The transactions involved both direct sales and exercises of employee stock options, all executed under a pre-planned Rule 10b5-1 sche…
J. E. Davis, the CEO and President of Quest Diagnostics Inc., completed a sale of company stock valued at approximately $1.94 million on June 1, 2026. This transaction occurred while the stock traded near $193.16. Beyond this executive action, the company has announced significant financial developments, including a quarterly cash dividend and a la…
Richard G. Steele, a senior executive at Moody's Corporation, recently sold company stock valued at $71,679 through a prearranged trading plan. This transaction occurs amidst varied analyst reports and macroeconomic indicators concerning the firm. Notably, BMO Capital Markets raised its price target for Moody's, while Mizuho lowered its estimate fo…
Atmus Filtration Technologies' Chief People Officer, Renee Swan, sold 2,566 shares of common stock on June 1, 2026. The sale generated approximately $116,103. This transaction occurred against a backdrop of positive company news, including an earnings per share (EPS) figure that surpassed analyst expectations and the appointment of new senior leade…
Jacob Suen, President and CEO of Airgain Inc., sold a portion of his common stock on June 1, 2026. This transaction occurred while the stock was trading near its recent highs, raising discussion about the company's valuation relative to its strategic pivot toward mission-critical connectivity solutions.
Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals Inc., executed a sale of common stock on June 1, 2026. This transaction occurred while the company's shares had risen significantly over the past year. Concurrently, Ligand announced its first-quarter 2026 earnings, which fell short of analyst expectations for both adjusted EPS and reven…
Stephanie Disher, the Chief Executive Officer of Atmus Filtration Technologies Inc., recently sold a significant block of company common stock. This insider selling activity occurred against a backdrop of generally positive corporate developments, including surpassing analyst expectations on first-quarter 2026 earnings per share and announcing a qu…
Executive activity at Optimum Communications, Inc. (NASDAQ:OPTU) recently included a planned sale of common stock by General Counsel Michael Olsen. This development occurs against a backdrop of mixed financial results for the quarter and a concurrent tender offer from a wholly-owned subsidiary.
Charles Masters, Senior Vice President of Atmus Filtration Technologies Inc., executed a sale of company stock totaling $130,763. This transaction occurred while the stock experienced volatility but was set against a backdrop of positive corporate news, including an earnings beat and a declared dividend. The firm also announced a key leadership app…
The Chief Financial Officer of Atmus Filtration Technologies Inc., Jack Kienzler, executed a sale of company stock valued at $232,207 on June 1, 2026. This transaction was detailed in an SEC filing and utilized proceeds to cover tax withholding related to the vesting of a launch grant award. Separately, the company announced positive financial resu…
Chief Legal Officer Michael Chen of Newegg Commerce, Inc. (NASDAQ:NEGG) recently sold shares of the company's common stock on June 1, 2026. The transaction details include the sale of 67 shares at a price of $18.18 per share, amounting to a total value of $1,218.This divestiture was executed under the framework of a Rule 10b5-1 trading plan. Follow…
Chief Scientific Officer (CSO) Jude Onyia executed a series of transactions involving Neurocrine Biosciences common stock, selling shares through a prearranged trading plan and simultaneously acquiring others by exercising non-qualified stock options. These personal trades occurred against the backdrop of significant corporate developments for Neur…
The recent filing disclosed a significant stock sale by Richard C. Cary, Controller and Chief Accounting Officer of Arthur J. Gallagher & Co., involving the disposition of company common shares. This activity is reported alongside details of Mr. Cary's remaining equity holdings, including derivative instruments and deferred compensation units. Furt…
